JP2018537480A5 - - Google Patents

Download PDF

Info

Publication number
JP2018537480A5
JP2018537480A5 JP2018530763A JP2018530763A JP2018537480A5 JP 2018537480 A5 JP2018537480 A5 JP 2018537480A5 JP 2018530763 A JP2018530763 A JP 2018530763A JP 2018530763 A JP2018530763 A JP 2018530763A JP 2018537480 A5 JP2018537480 A5 JP 2018537480A5
Authority
JP
Japan
Prior art keywords
alkyl
alkoxy
substituted
independently
substituents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018530763A
Other languages
English (en)
Japanese (ja)
Other versions
JP6669868B2 (ja
JP2018537480A (ja
Filing date
Publication date
Priority claimed from CN201510900083.4A external-priority patent/CN106854207B/zh
Application filed filed Critical
Publication of JP2018537480A publication Critical patent/JP2018537480A/ja
Publication of JP2018537480A5 publication Critical patent/JP2018537480A5/ja
Application granted granted Critical
Publication of JP6669868B2 publication Critical patent/JP6669868B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018530763A 2015-12-08 2016-12-08 フタラジン誘導体、その製造方法、医薬組成物および使用 Active JP6669868B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510900083.4 2015-12-08
CN201510900083.4A CN106854207B (zh) 2015-12-08 2015-12-08 呔嗪类衍生物、其制备方法、药物组合物和用途
PCT/CN2016/108975 WO2017097217A1 (zh) 2015-12-08 2016-12-08 呔嗪类衍生物、其制备方法、药物组合物和用途

Publications (3)

Publication Number Publication Date
JP2018537480A JP2018537480A (ja) 2018-12-20
JP2018537480A5 true JP2018537480A5 (enExample) 2019-02-28
JP6669868B2 JP6669868B2 (ja) 2020-03-18

Family

ID=59013670

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018530763A Active JP6669868B2 (ja) 2015-12-08 2016-12-08 フタラジン誘導体、その製造方法、医薬組成物および使用

Country Status (5)

Country Link
US (1) US11220503B2 (enExample)
EP (1) EP3388433B1 (enExample)
JP (1) JP6669868B2 (enExample)
CN (1) CN106854207B (enExample)
WO (1) WO2017097217A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2019233183B2 (en) * 2018-03-12 2024-02-01 Shanghai SIMR Biotechnology Co., Ltd Phthalazine isoxazole alkoxy derivatives, preparation method thereof, pharmaceutical composition and use thereof
CN112979655A (zh) 2019-12-16 2021-06-18 上海赛默罗生物科技有限公司 三唑并哒嗪类衍生物、其制备方法、药物组合物和用途
MX2023006231A (es) * 2020-12-01 2023-08-24 Kalvista Pharmaceuticals Ltd Inhibidores de enzimas.
CN112441901B (zh) * 2020-12-15 2023-08-29 山东泰和科技股份有限公司 一种乙酸酐的合成方法
CN116008443B (zh) * 2023-03-28 2023-06-30 上海赛默罗生物科技有限公司 α5-GABAA受体调节剂类药物中有关物质的检测方法
CN119019425A (zh) * 2023-05-26 2024-11-26 武汉人福创新药物研发中心有限公司 一种作为α5-GABAA受体调节剂的杂环化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9112504D0 (en) 1991-06-11 1991-07-31 Merck Sharp & Dohme Cell line
ES2296064T3 (es) 1992-12-10 2008-04-16 MERCK SHARP & DOHME LIMITED Lineas celulares transfectadas de manera estable que expresan receptores gaba-a humanos con una combinacion de subunidades alfa-2, beta-3 y gamma-2.
ES2179490T3 (es) 1997-05-08 2003-01-16 Merck Sharp & Dohme Derivados de 1,2,4-triazolo(3,4-a)ftalazina sustituidos como ligandos de gaba alfa 5.
GB9715977D0 (en) 1997-07-29 1997-10-01 Merck Sharp & Dohme Therapeutic agents
US6297235B1 (en) 1997-08-28 2001-10-02 Merck Sharp & Dohme Ltd. Triazolopyridazine derivatives for treating anxiety and enhancing cognition
MXPA02004735A (es) 1999-11-12 2003-01-28 Orive Javier Uhthoff Compuestos heteroaromaticos, biciclicos y triciclicos.
GB0028583D0 (en) * 2000-11-23 2001-01-10 Merck Sharp & Dohme Therapeutic compounds
US20050043982A1 (en) * 2003-08-22 2005-02-24 Nguyen Vinh Dinh Contextual workflow modeling
WO2005041971A1 (en) * 2003-10-21 2005-05-12 Merck & Co., Inc. Triazolo-pyridazine compounds and derivatives thereof useful in the treatment of neuropathic pain
US10206921B2 (en) 2009-06-03 2019-02-19 The Regents Of The University Of California Methods and compositions for treating a subject for central nervous system (CNS) injury
US20150374705A1 (en) 2012-02-14 2015-12-31 Shanghai Institues for Biological Sciences Substances for treatment or relief of pain

Similar Documents

Publication Publication Date Title
JP2019532078A5 (enExample)
JP2013530236A5 (enExample)
JP2014503525A5 (enExample)
JP2015511958A5 (enExample)
JP2019515952A5 (enExample)
RU2017101829A (ru) Пиразоловые соединения в качестве модуляторов fshr и пути их применения
JP2015509535A5 (enExample)
RU2021100620A (ru) Оксистеролы и способы их применения
RU2019115113A (ru) Оксистеролы и способы их применения
JP2016510758A5 (enExample)
JP2015537020A5 (enExample)
JP2018520205A5 (enExample)
JP2016540742A5 (enExample)
JP2017516796A5 (enExample)
JP2013533883A5 (enExample)
JP2016513108A5 (ja) 治療用化合物
JP2016519165A5 (enExample)
JP2020527175A5 (enExample)
HRP20170695T1 (hr) Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova uporaba u obliku lijeka
JP2017525699A5 (enExample)
HRP20180973T1 (hr) Supstituirani tiazolski ili oksazolski antagonisti p2x7 receptora
EA201990688A1 (ru) Полиморфные формы соединения, представляющего собой ингибитор киназ, содержащая их фармацевтическая композиция, способ их получения и их применение
JP2016510000A5 (ja) 治療用化合物
JP2015516427A5 (enExample)
JP2016503010A5 (enExample)